Company / Revenue
Axsome Therapeutics, Inc. Revenue History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$638.5M
FY2025
5-year range
$0 / $638.5M
FY2022-FY2025
Trend
+65.5%
vs FY2024
Sector context
#56 of 155
Health Care
What the data says
At $638M, Axsome Therapeutics, Inc.'s revenue ranks #56 of 155 in the Health Care sector. Revenue has increased for 3 consecutive years, from $0 in FY2022 to $638M in FY2025.
Based on SEC 10-K filings.
$638M in FY2025.
Improved from $271M to $638M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#56 of 155 in Health CareTop 36% of 155This company $638.5M Sector average $4.5B
▼
-85.7% below sector average
Key checks
Key Insights
- In FY2025, revenue increased 65.5% year-over-year.
- Ranks #56 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $638.5M | +65.5% |
| FY2024 | $385.7M | +42.5% |
| FY2023 | $270.6M | - |
| FY2022 | $0 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026